These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21896780)

  • 1. Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor γ2 expression.
    Ahn YH; Yang Y; Gibbons DL; Creighton CJ; Yang F; Wistuba II; Lin W; Thilaganathan N; Alvarez CA; Roybal J; Goldsmith EJ; Tournier C; Kurie JM
    Mol Cell Biol; 2011 Nov; 31(21):4270-85. PubMed ID: 21896780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZPK/DLK and MKK4 form the critical gateway to axotomy-induced motoneuron death in neonates.
    Itoh T; Horiuchi M; Ikeda RH; Xu J; Bannerman P; Pleasure D; Penninger JM; Tournier C; Itoh A
    J Neurosci; 2014 Aug; 34(32):10729-42. PubMed ID: 25100604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and mutation analyses of MKK4, a candidate tumour suppressor gene encoded by chromosome 17p, in human gastric adenocarcinoma.
    Chae KS; Ryu BK; Lee MG; Byun DS; Chi SG
    Eur J Cancer; 2002 Oct; 38(15):2048-57. PubMed ID: 12376211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Map2k4δ - identification and functional characterization of a novel Map2k4 splice variant.
    Haeusgen W; Tueffers L; Herdegen T; Waetzig V
    Biochim Biophys Acta; 2014 May; 1843(5):875-84. PubMed ID: 24487067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course.
    Xin W; Yun KJ; Ricci F; Zahurak M; Qiu W; Su GH; Yeo CJ; Hruban RH; Kern SE; Iacobuzio-Donahue CA
    Clin Cancer Res; 2004 Dec; 10(24):8516-20. PubMed ID: 15623633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the mitogen-activated protein kinase kinase 4 (MAP2K4) tumor suppressor gene in ovarian cancer.
    Davis SJ; Choong DY; Ramakrishna M; Ryland GL; Campbell IG; Gorringe KL
    BMC Cancer; 2011 May; 11():173. PubMed ID: 21575258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new prognosis prediction model combining TNM stage with MAP2K4 and JNK in postoperative pancreatic cancer patients.
    Liu XD; Zhang ZW; Wu HW; Liang ZY
    Pathol Res Pract; 2021 Jan; 217():153313. PubMed ID: 33341545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1.
    Roybal JD; Zang Y; Ahn YH; Yang Y; Gibbons DL; Baird BN; Alvarez C; Thilaganathan N; Liu DD; Saintigny P; Heymach JV; Creighton CJ; Kurie JM
    Mol Cancer Res; 2011 Jan; 9(1):25-35. PubMed ID: 21115742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Theoretical proposal: allele dosage of MAP2K4/MKK4 could rationalize frequent 17p loss in diverse human cancers.
    Cunningham SC; Gallmeier E; Hucl T; Dezentje DA; Abdelmohsen K; Gorospe M; Kern SE
    Cell Cycle; 2006 May; 5(10):1090-3. PubMed ID: 16721048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor.
    Teng DH; Perry WL; Hogan JK; Baumgard M; Bell R; Berry S; Davis T; Frank D; Frye C; Hattier T; Hu R; Jammulapati S; Janecki T; Leavitt A; Mitchell JT; Pero R; Sexton D; Schroeder M; Su PH; Swedlund B; Kyriakis JM; Avruch J; Bartel P; Wong AK; Tavtigian SV
    Cancer Res; 1997 Oct; 57(19):4177-82. PubMed ID: 9331070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.
    Yeddula N; Xia Y; Ke E; Beumer J; Verma IM
    Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6476-85. PubMed ID: 26542681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-27a promotes proliferation, migration and invasion by targeting MAP2K4 in human osteosarcoma cells.
    Pan W; Wang H; Jianwei R; Ye Z
    Cell Physiol Biochem; 2014; 33(2):402-12. PubMed ID: 24556602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
    Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
    Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7.
    Vander Griend DJ; Kocherginsky M; Hickson JA; Stadler WM; Lin A; Rinker-Schaeffer CW
    Cancer Res; 2005 Dec; 65(23):10984-91. PubMed ID: 16322247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors.
    Wang L; Pan Y; Dai JL
    Oncogene; 2004 Aug; 23(35):5978-85. PubMed ID: 15184866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1.
    Chen HW; Lee JY; Huang JY; Wang CC; Chen WJ; Su SF; Huang CW; Ho CC; Chen JJ; Tsai MF; Yu SL; Yang PC
    Cancer Res; 2008 Sep; 68(18):7428-38. PubMed ID: 18794131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.
    Maity TK; Venugopalan A; Linnoila I; Cultraro CM; Giannakou A; Nemati R; Zhang X; Webster JD; Ritt D; Ghosal S; Hoschuetzky H; Simpson RM; Biswas R; Politi K; Morrison DK; Varmus HE; Guha U
    Cancer Discov; 2015 May; 5(5):534-49. PubMed ID: 25735773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway.
    Xia D; Srinivas H; Ahn YH; Sethi G; Sheng X; Yung WK; Xia Q; Chiao PJ; Kim H; Brown PH; Wistuba II; Aggarwal BB; Kurie JM
    J Biol Chem; 2007 Feb; 282(6):3507-19. PubMed ID: 17158870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation rate of MAP2K4/MKK4 in breast carcinoma.
    Su GH; Song JJ; Repasky EA; Schutte M; Kern SE
    Hum Mutat; 2002 Jan; 19(1):81. PubMed ID: 11754110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial-mesenchymal transition, and is regulated by Wnt7A through PPARgamma in non-small cell lung cancer.
    Tennis MA; Van Scoyk MM; Freeman SV; Vandervest KM; Nemenoff RA; Winn RA
    Mol Cancer Res; 2010 Jun; 8(6):833-43. PubMed ID: 20501643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.